Johnson & Johnson seeks approval of pediatric indications for TREMFYA
by
Contributor since / Followers
Contributor since / Followers
3 weeks ago
Sundry Photography/iStock Editorial via Getty Images
- Johnson & Johnson (NYSE:JNJ) submitted two supplemental Biologics License Applications to the U.S. FDA seeking approval of TREMFYA for treating children 6 years and older with moderate-to-severe plaque psoriasis (PsO) and children 5 years of age and older with active juvenile psoriatic arthritis.
- The submission is based on data from the late stage study in pediatric patients with moderate to severe plaque PsO and bridging pharmacokinetic data from the Phase 3 VOYAGE 1 and 2 studies.
- Source: Press Release